AmerisourceBergen Declares Quarterly Dividend
February 09 2017 - 9:26AM
Business Wire
The Board of Directors of AmerisourceBergen Corporation (NYSE:
ABC) today declared a quarterly dividend of $0.365 per common
share, payable March 6, 2017, to stockholders of record at the
close of business on February 21, 2017.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical
sourcing and distribution services companies, helping both
healthcare providers and pharmaceutical and biotech manufacturers
improve patient access to products and enhance patient care. With
services ranging from drug distribution and niche premium logistics
to reimbursement and pharmaceutical consulting services,
AmerisourceBergen delivers innovative programs and solutions across
the pharmaceutical supply channel in human and animal health. With
over $145 billion in annual revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 19,000
people. AmerisourceBergen is ranked #12 on the Fortune 500 list.
For more information, go to www.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project,"
"intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible,"
"assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These
statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These
statements are not guarantees of future performance and are based
on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable
trends in brand and generic pharmaceutical pricing, including in
rate or frequency of price inflation or deflation; competition and
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; substantial defaults
in payment, material reduction in purchases by or the loss,
bankruptcy or insolvency of a major customer; changes to the
customer or supplier mix; the retention of key customer or supplier
relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; the
disruption of AmerisourceBergen's cash flow and ability
to return value to its stockholders in accordance with its past
practices; risks associated with the strategic, long-term
relationship between Walgreens Boots Alliance,
Inc. and AmerisourceBergen, including with respect to the
pharmaceutical distribution agreement and/or the global sourcing
arrangement; changes in the United States healthcare and
regulatory environment, including changes that could impact
prescription drug reimbursement
under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government
enforcement initiatives to detect and prevent suspicious orders of
controlled substances and the diversion of controlled substances;
federal and state prosecution of alleged violations of related laws
and regulations, and any related litigation, including shareholder
derivative lawsuits or other disputes relating to our distribution
of controlled substances; increased federal scrutiny and qui tam
litigation for alleged violations of fraud and abuse laws and
regulations and/or any other laws and regulations governing the
marketing, sale, purchase and/or dispensing of pharmaceutical
products or services and any related litigation; material adverse
resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do
not perform as expected, or that are difficult to integrate or
control, including the integration of PharMEDium, or the inability
to capture all of the anticipated synergies related thereto;
regulatory action in connection with the production, labeling or
packaging of products compounded by our compounded sterile
preparations (CSP) business; declining economic conditions
in the United States and abroad; financial market
volatility and disruption; the loss, bankruptcy or insolvency of a
major supplier; interest rate and foreign currency exchange rate
fluctuations; managing foreign expansion, including non-compliance
with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and
economic sanctions and import laws and regulations; malfunction,
failure or breach of sophisticated information systems to operate
as designed; risks generally associated with data privacy
regulation and the international transfer of personal data; changes
in tax laws or legislative initiatives that could adversely
affect AmerisourceBergen's tax positions and/or
AmerisourceBergen’s tax liabilities or adverse resolution of
challenges to AmerisourceBergen's tax positions; natural
disasters or other unexpected events that
affect AmerisourceBergen's operations; the impairment of
goodwill or other intangible assets, resulting in a charge to
earnings; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors
affecting AmerisourceBergen's business generally. Certain
additional factors that management believes could cause actual
outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk
Factors) in the Company’s Annual Report on Form 10-K for the fiscal
year ended September 30, 2016 and elsewhere in that
report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170209005764/en/
AmerisourceBergen CorporationKeri P. MattoxVice
President, Corporate & Investor
Relations610-576-7801kmattox@amerisourcebergen.comorBennett
S. MurphyManager, Corporate & Investor
Relations610-727-3693bmurphy@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Sep 2023 to Sep 2024